Results 121 to 130 of about 65,632 (246)

SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis

EMBO Molecular Medicine, 2012
Loss of SPRY2 and activation of receptor tyrosine kinases are common events in prostate cancer (PC). However, the molecular basis of their interaction and clinical impact remains to be fully examined.
Meiling Gao, Rachana Patel, Imran Ahmad, Janis Fleming, Joanne Edwards, Stuart McCracken, Kanagasabai Sahadevan, Morag Seywright, Jim Norman, Owen Sansom, Hing Y. Leung   +10 more
doaj   +1 more source

Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first‐line treatment in patients
Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang   +9 more
wiley   +1 more source

Extracellular portions of EGF receptor with TGFa and ErbB-2 [PDF]

Acta Crystallographica Section A Foundations of Crystallography, 2002
T. P. J. Garrett, M. Z. Lou, N. M. McKern, T. E. Adams, G. O. Lovrecz, R. N. Jorissen, E. C. Nice, A. W. Burgess, C. W. Ward   +8 more
openaire   +1 more source

Multi‐omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
We developed three UC clusters, applicable for MIBC and NMIBC, which were validated using transcriptomic- and proteomic datasets. Publically available UC cell lines were assigned to the clusters, to have in vitro models representing each cluster. The clusters differ in molecular and biological signatures, with distinct prognostic and therapeutic ...
Nils C. H. van Creij, Piotr Tymoszuk, Florian Handle, Andreas Seeber, Teresa Sellemond, Agnieszka Martowicz, Eva Comperat, Hamed Wafa, Steffen Ormanns, Michael Günther, Walther Parson, Maxim Noeparast, Frédéric R. Santer, José Daniel Subiela, Petros Grivas, Roger Li, Zoran Culig, Renate Pichler   +17 more
wiley   +1 more source

Non‐HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 3, March 2026.
ABSTRACT Aim The genetic loci, ERBB2/IKZF3/GSDMB/ORMDL3 on chromosome 17q, and ERBB3/IKZF4 on chromosome 12q represent confirmed non‐HLA risk factors for the development of autoimmunity and progression to type 1 diabetes (T1D). It is unknown whether both regions can interact to influence the progression of T1D.
Ina M. Mertens, Bart Keymeulen, Frans K. Gorus, Mark Van De Casteele, the Belgian Diabetes Registry   +4 more
wiley   +1 more source

Predictive value of her-2 in breast cancer: Chemotherapy [PDF]

Archive of Oncology, 2002
Stamatović Ljiljana, Šušnjar Snežana, Nešković-Konstantinović Zora, Vasović Suzana, Tomašević Zorica I., Nikolić-Vukosavljević Dragica   +5 more
doaj   +1 more source

Distinct Clinicopathological Features of HER2‐Negative, HER2‐Low, and HER2‐Overexpressing Urothelial Carcinoma in a Large Chinese Cohort

Cancer Medicine
Purpose To investigate the expression patterns of Human Epidermal Growth Factor Receptor 2 (HER2) and their clinicopathological associations across the full spectrum (negative, low, and overexpression) in a large cohort of Chinese urothelial carcinoma ...
Shanshan Wang, Dingwei Ye, Li Yang, Fan Cheng, Tiejun Yang, Xiaoping Zhang, Zhixian Yu, Qingyun Zhang, Yong Yang   +8 more
doaj   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source